Endoscopic Resection for Small Rectal Neuroendocrine Tumors

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different methods for treating small rectal neuroendocrine tumors (NETs), which are a type of cancer that can develop in the rectum. The trial aims to compare the effectiveness of two techniques: modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic mucosal resection with a ligation device (ESMR-L). Both techniques have shown promise in previous studies, but this trial will provide more detailed information by looking at multiple centers to see which method may have advantages or disadvantages.

To participate in the trial, individuals must be between 18 and 80 years old and have a suspected or confirmed diagnosis of a small rectal NET that is 10 mm or smaller. They also need to be willing to receive one of the two treatment options and provide consent. However, not everyone will be eligible; for example, individuals with serious health issues, those who have had previous treatments for their tumors, or those who are pregnant may not qualify. If you join the trial, you can expect to receive one of the two treatment methods and will be monitored closely by medical professionals throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age from 18 to 80 years;
• • 2. With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
• • 3. With tumor size ≤10 mm assessed by colonoscopy;
• • 4. Plan to receive mEMR-C or mEMR-L treatment and provide written informed consent;
• Exclusion Criteria:
• • 1. Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each center;
• • 2. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
• • 3. Rectal NET with lymph node metastasis or distant metastasis;
• • 4. Received resection of rectal neuroendocrine tumor by other surgical procedures;
• • 5. Multiple rectal neuroendocrine tumors;
• • 6. Vulnerable groups such as pregnant women or patients with mental disorders;
• • 7. Poor compliance, unable to cooperate with treatment.